Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

(RTTNews) - Globus Medical (GMED), a musculoskeletal solutions company, Thursday agreed to acquire Nevro Corp. (NVRO), a medical device company, in an all-cash transaction. Under the terms of the ...

Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Globus Medical has a 12 month low of $49.33 and a 12 month high of $94.93. Globus Medical ( NYSE:GMED – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th.